Drug intelligence / Profile preview

neostigmine + vecuronium

Development stage
Unknown
Modality
Small Molecules
Administration
Intravenous
01

Overview

Neostigmine + vecuronium is a combination of two drugs used in anesthesia practice. Vecuronium is a non-depolarizing neuromuscular blocking agent (muscle relaxant) that acts by competitively inhibiting acetylcholine at the neuromuscular junction, resulting in skeletal muscle relaxation during surgery or mechanical ventilation[5][6]. Neostigmine is a reversible cholinesterase inhibitor that increases acetylcholine levels at the neuromuscular junction by inhibiting acetylcholinesterase, thereby reversing the effects of non-depolarizing muscle relaxants like vecuronium[4][7]. This combination is commonly used to induce and then reverse skeletal muscle paralysis during surgical procedures under general anesthesia. Neostigmine is typically administered near the end of surgery to antagonize residual neuromuscular blockade caused by vecuronium, facilitating recovery of normal muscle function[1][2].

02

Targets

AcetylcholinesteraseNicotinic Acetylcholine Receptor

Beyond the preview

Go deeper on neostigmine + vecuronium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on neostigmine + vecuronium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call